FOXO1 and soft tissue sarcoma: As reported by Gallego et al in the European pediatric Soft tissue sarcoma Study Group (EpSSG) cohort, the 5-year OS of patients with FOXO1 fusion-positive tumors was 51.6%, compared to 76% for those with FOXO1 fusion-negative tumors, which approached statistical significance (P = .069).[12]